Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
Add more filters










Publication year range
1.
Drug Res (Stuttg) ; 66(7): 384-92, 2016 Jul.
Article in English | MEDLINE | ID: mdl-27281448

ABSTRACT

A pooled analysis is presented of 7 placebo-controlled RCT that investigated lozenges containing ambroxol for pain relief in acute sore throat.2 242 patients were treated with different ambroxol doses or control treatments, 2 183 were evaluable for efficacy. The present analysis is focused on the recommended dose of 20 mg (AXL20): 856 patients were treated with AXL20, 847 with matched placebo lozenges (PL).The average reduction in pain intensity over the first 3 h after the first AXL20 ranged from 38% to 52% of the maximum achievable effect (MAE). The overall treatment difference between AXL20 and PL was 11% (95% CI: 8-13%) of the MAE (post-hoc meta-analysis). The corresponding NNT was 6.0 (CI: 4.7-8.4) for an average pain reduction from baseline of 33% of the MAE over the first 3 h.71.9, 79.0, and 85.3% of the AXL20-patients scored the efficacy as "very good or good" at the end of the 1(st), 2(nd) and 3(rd) day, respectively, vs. 57.5, 64.4, and 70.4% of the PL-patients resulting in odds ratios of 1.9 (CI: 1.5-2.3) for the 1(st), 2.1 (CI: 1.7-2.6) for the 2(nd) and 2.43 (CI: 1.8-3.3) for the 3(rd) day.At the end of treatment 'no redness' or 'slightly red' was scored on pharyngeal inspection in 84.4% and 77.3% of AXL20- and PL-patients (OR: 1.6, CI: 1.3-1.9).AXL20-treatment was well tolerated and is safe and efficacious for acute uncomplicated sore throat of recent onset in adolescent and adult patients.


Subject(s)
Ambroxol/adverse effects , Ambroxol/therapeutic use , Pharyngitis/drug therapy , Administration, Oral , Adolescent , Adult , Aged , Aged, 80 and over , Ambroxol/administration & dosage , Double-Blind Method , Expectorants/administration & dosage , Expectorants/adverse effects , Expectorants/therapeutic use , Female , Humans , Male , Meta-Analysis as Topic , Middle Aged , Pain Measurement/drug effects , Sucking Behavior , Tablets , Young Adult
2.
Ultraschall Med ; 32 Suppl 2: E51-6, 2011 Dec.
Article in German | MEDLINE | ID: mdl-21618167

ABSTRACT

PURPOSE: Scrotal ultrasound, color Doppler and spectral Doppler analysis of intratesticular arteries are the most common and important examinations in boys with scrotal pain. In the existing literature information concerning feasibility and reference values of color Doppler and spectral Doppler in small testes is inconsistent. MATERIALS AND METHODS: In the present study 102 boys from 2 days to 16 years old without present or anamnestic scrotal disease were examined in a standardized manner. Using linear scanners (9 - 14 mHz), testicular volumetry and spectral Doppler analysis of typical intratesticular arteries were performed and the paratesticular structures were examined. For analysis we grouped the testes by volume and compared the measured values V. max syst., V. max enddiast., and RI. RESULTS: In all test subjects a complete examination with spectral Doppler analysis of intratesticular arteries could be performed. With increasing testicular volume, there is a linear increase in blood flow velocities V. max syst. and V. enddiast. Irrespective of age and testicular volume, the RI of the intratesticular arteries is 0.54 ± 0.08. CONCLUSION: In contrast to published data, this study shows that color Doppler and spectral Doppler of testicular arteries can be regularly performed even in small testes of less than 1 ml. Reference values for blood flow velocities and RI were found and should improve the diagnostic value of testicular ultrasound examinations in children.


Subject(s)
Image Interpretation, Computer-Assisted/methods , Scrotum/diagnostic imaging , Testis/blood supply , Testis/diagnostic imaging , Ultrasonography, Doppler, Color/methods , Ultrasonography, Doppler, Duplex/methods , Adolescent , Arteries/diagnostic imaging , Child , Child, Preschool , Fourier Analysis , Humans , Infant , Infant, Newborn , Male , Organ Size/physiology , Reference Values , Sensitivity and Specificity
3.
Diabetes Nutr Metab ; 17(3): 163-8, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15334794

ABSTRACT

In a double blind, randomised study, 19 patients suffering from mild-to-moderate symptomatic diabetic neuropathy (Total Symptom Score, NTSS 4-16) received either treatment with the new transcutaneous electrical nerve stimulation (TENS) device "Salutaris" (verum group) or a placebo treatment with an identical but electrically inactive device (placebo group). Stimulation pads were placed at the anatomical localisation of the peroneal nerve and stimulation was performed using a low frequency mode. At baseline (V1), after 6 (V2), and 12 (V3) wk of treatment, the patients' symptoms were registered using the new total symptom score (NTSS-6) and a visual analogue scale (VAS). In addition, sensory nerve thresholds (temperature, vibration, pain) and microvascular function were measured at the lower limb at baseline and after 12 wk of treatment. Active TENS-treatment resulted in a significant improvement in NTSS-6 score after 6 wk (-42%) and after 12 wk (-32%) of treatment (baseline: 10.0+/-3.3, 6 wk: 5.8+/-5.0, p<0.05; 12 wk: 6.8+/-3.9, p=0.05; placebo group: baseline: 7.6+/-3.1; 6 wk: 8.1+/-5.1, n.s.; 12 wk: 6.5+/-6.1, n.s.). Subanalysis of the different qualities of the NTSS-score revealed an improvement in numbness (2.2+/-1.0 to 1.6+/-1.3; p<0.03); lancinating pain (1.6+/-1.1 to 0.6+/-0.9; p<0.02) and allodynia (1.4+/-1.6 to 0.5+/-1.0; p<0.05). Also, a significant improvement in the VAS rating was found after 6 wk of TENS therapy (19.8+/-5.0 to 14.4+/-9.6; p<0.05), while no change was observed in the placebo arm. In conclusion, our study indicates that the new TENS device "Salutaris" is a convenient, non-pharmacological option for primary or adjuvant treatment of painful diabetic neuropathy.


Subject(s)
Diabetic Neuropathies/therapy , Transcutaneous Electric Nerve Stimulation , Aged , Double-Blind Method , Female , Humans , Male , Middle Aged , Pain Measurement , Peroneal Nerve , Placebos , Surveys and Questionnaires , Time Factors , Transcutaneous Electric Nerve Stimulation/instrumentation
4.
Am J Reprod Immunol ; 50(4): 309-15, 2003 Oct.
Article in English | MEDLINE | ID: mdl-14672333

ABSTRACT

PROBLEM: The hypothesis that indoleamine 2,3-dioxygenase (IDO) is necessary to regulate lymphocyte functions at the feto-maternal interface has been postulated, although a possible role of tryptophan (Trp) depletion in the T-cell tolerance during insemination as well as implantation has not been previously investigated. METHOD OF STUDY: Allogeneic phytohaemagglutinin stimulated lymphocytes were supplemented with pre-implantation embryo supernatant (PES), seminal plasma (SP), spermatozoa culture supernatant (SCS), spermatozoa, trophoblast cells, or placenta explant culture supernatants, and analyzed for expression of CD25, CD71, and CD69. Trp-degrading activity was assessed by addition of 1-methyl-Tryptophan or L-Trp. RESULTS: PES, SP, trophoblast, and explant supernatants reduced the expression of CD25 in CD3 lymphocytes. Inhibition of IDO as well as Trp supplementation prevented these effects. CONCLUSIONS: These data suggest that the expression of interleukin-2 (IL-2) receptor in maternal T lymphocytes is normally suppressed by Trp catabolism, and that either abnormal IDO levels or substances influencing IDO activity might lead to non-adequate immune responses on sperm, harm the conceptus or even initiate fetal rejection.


Subject(s)
Blastocyst/immunology , Immune Tolerance/drug effects , Spermatozoa/immunology , Trophoblasts/immunology , Tryptophan/analogs & derivatives , Tryptophan/pharmacology , Adult , Female , Humans , In Vitro Techniques , Indoleamine-Pyrrole 2,3,-Dioxygenase , Male , Maternal-Fetal Exchange/immunology , Pregnancy , Receptors, Interleukin-2/metabolism , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Tryptophan Oxygenase/metabolism
5.
J Mol Biol ; 328(3): 705-19, 2003 May 02.
Article in English | MEDLINE | ID: mdl-12706727

ABSTRACT

The conformation of the AB-loop and EF-loop of bacteriorhodopsin and of the fourth cytoplasmic loop (helix VIII) of bovine rhodopsin were assessed by a combination of time-resolved fluorescence depolarization and site-directed fluorescence labeling. The fluorescence anisotropy decays were measured employing a tunable Ti:sapphire laser/microchannel plate based single-photon counting apparatus with picosecond time resolution. This method allows measurement of the diffusional dynamics of the loops directly on a nanosecond time-scale. We implemented the method to study model peptides and two-helix systems representing sequences of bacteriorhodopsin. Thus, we systematically analyzed the anisotropic behavior of four different fluorescent dyes covalently bound to a single cysteine residue on the protein surface and assigned the anisotropy decay components to the modes of motion of the protein and its segments. We have identified two mechanisms of loop conformational changes in the functionally intact proteins bacteriorhodopsin and bovine rhodopsin. First, we found a surface potential-dependent transition between two conformational states of the EF-loop of bacteriorhodopsin, detected with the fluorescent dye bound to position 160. A transition between the two conformational states at 150mM KCl and 20 degrees C requires a surface potential change that corresponds to Deltasigma approximately -1.0e(-)/bacteriorhodopsin molecule. We suggest, that the surface potential-based switch of the EF-loop is the missing link between the movement of helix F and the transient surface potential change detected during the photocycle of bacteriorhodopsin. Second, in the visual pigment rhodopsin, with the fluorescent dye bound to position 316, a particularly striking pH-dependent conformational change of the fourth loop on the cytoplasmic surface was analyzed. The loop mobility increased from pH 5 to 8. The midpoint of this transition is at pH 6.2 and correlates with the midpoint of the pH-dependent equilibrium between the active metarhodopsin II and the inactive metarhodopsin I state.


Subject(s)
Bacteriorhodopsins/chemistry , Rhodopsin/chemistry , Animals , Anisotropy , Cattle , Fluorescent Dyes , Hydrogen-Ion Concentration , Kinetics , Membrane Proteins/chemistry , Models, Molecular , Protein Structure, Secondary , Protein Structure, Tertiary , Spectrometry, Fluorescence , Temperature
6.
Acta Diabetol ; 39(1): 1-6, 2002 Apr.
Article in English | MEDLINE | ID: mdl-12043933

ABSTRACT

Topical treatment with capsaicin cream has been shown to be successful in the treatment of different symptomatic nerve disorders like diabetic neuropathy. Conflicting data exist on the effect of capsaicin on nerve function and neurovascular control especially in patients with diabetic neuropathy. The aim of this pilot study was to investigate the impact of topical capsaicin application on small nerve fibre function and neurovascular control. Capsaicin cream was applied to the feet of 13 patients with symptomatic diabetic neuropathy over a period of 8 weeks. Before and during the treatment period, we investigated the total symptoms score, the vibration, thermal (heat and cold) and pain perception thresholds, and the neurovascular responses to heat and acetylcholine stimuli. In addition, the serum plasma levels of substance P, a neurotransmitter of nociceptor C-fibres, were measured. A significant improvement in total symptoms score was observed during topical capsaicin treatment (18.3+/-3.2 vs. 14.3+/-3.3; p<0.05). An improvement in the heat perception threshold was also found (12.7+/-0.4 degrees C vs. 11.4+/-0.7 degrees C: p<0.05), while other sensory nerve fibre functions remained unchanged. No significant change in neurovascular control was observed, neither after mild thermal injury nor after stimulation with acetylcholine. Serum substance P levels increased after initiation of topical capsaicin treatment (72.9+/-5.8 pg/ml vs. 81.7+/-5.0 pg/ml; p<0.05), but returned to baseline levels during further treatment (77.4+/-8.3 pg/ml: n.s.). In conclusion, topical treatment with capsaicin cream over a period of 8 weeks in patients with symptomatic diabetic neuropathy is effective without adverse effects on nerve fibre function or neurovascular control.


Subject(s)
Capsaicin/therapeutic use , Diabetic Neuropathies/drug therapy , Nerve Fibers/physiology , Phytotherapy , Administration, Topical , Capsaicin/administration & dosage , Diabetes Mellitus, Type 1/physiopathology , Diabetes Mellitus, Type 2/physiopathology , Diabetic Neuropathies/physiopathology , Female , Humans , Male , Middle Aged , Nerve Fibers/drug effects , Pilot Projects , Sensory Thresholds/drug effects , Sensory Thresholds/physiology
7.
Org Lett ; 2(24): 3877-9, 2000 Nov 30.
Article in English | MEDLINE | ID: mdl-11101442

ABSTRACT

Palladium-catalyzed additions of disilanes, silylboranes, silylstannanes, and silyl cyanides across the double bond of bicyclopropylidene proceed with remarkable ease by two modes yielding either bicyclopropyl or cyclopropylidenepropane derivatives.

8.
Exp Clin Endocrinol Diabetes ; 108(3): 164-7, 2000.
Article in English | MEDLINE | ID: mdl-10926310

ABSTRACT

Morphological and immunohistochemical studies in diabetic subjects have shown a depletion of the neuropeptide substance P (SP) in the central and peripheral nervous system. This is the first study investigating serum levels of substance P in type 1 diabetes patients (n=50) and controls (n=75) by means of an enzyme immunoassay. The serum level of SP was significantly decreased in the diabetic group compared to the control group (10.12+/-0.29 vs. 12.25+/-0.38 pg/ml; p<0.0001). In diabetic patients, there was no correlation of substance P levels with age, serum creatinine, albuminuria, total cholesterol, HDL- or LDL-cholesterol, triglycerides, HbA1c, type or duration of diabetes and gender. Furthermore, there was no difference in serum levels of SP in patients with or without retinopathy, but SP was significantly decreased in patients with neuropathy (9.59+/-0.48 vs. 10.78+/-0.83 pg/ml; p=0.04). These data show that SP is decreased in serum of type 1 diabetes patients, especially in those with diabetic neuropathy. Subsequent and already ongoing prospective studies in well validated diabetic patients with neuropathy may characterize the impact of this neurogenic marker in the course of diabetic neuropathy.


Subject(s)
Diabetes Mellitus, Type 1/blood , Substance P/blood , Adolescent , Adult , Aged , Cholesterol/blood , Female , Humans , Immunoenzyme Techniques , Male , Middle Aged , Reference Values
9.
Clin Sci (Lond) ; 98(3): 283-90, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10677386

ABSTRACT

This study was conducted to evaluate the influence of proinsulin C-peptide on erythrocyte Na(+),K(+)-ATPase and endothelial nitric oxide synthase activities in patients with type I diabetes. In a randomized double-blind study design, ten patients with type I diabetes received intravenous infusions of either human C-peptide or physiological saline on two different occasions. C-peptide was infused at a rate of 3 pmol.min(-1).kg(-1) for 60 min, and thereafter at 10 pmol.min(-1).kg(-1) for 60 min. At baseline and after 60 and 120 min, laser Doppler flow (LDF) was measured following acetylcholine iontophoresis or mild thermal stimulation (44 degrees C), and venous blood samples were collected to determine plasma cGMP levels and erythrocyte membrane Na(+),K(+)-ATPase activity. The LDF response to acetylcholine increased during C-peptide infusion and decreased during saline infusion [18.6+/-19.2 and -13.2+/-9.4 arbitrary units respectively; mean+/-S.E.M.; P<0.05). No significant change in LDF was observed after thermal stimulation. The baseline plasma concentration of cGMP was 5.5+/-0.6 nmol.l(-1); this rose to 6.8+/-0.9 nmol.l(-1) during C-peptide infusion (P<0.05). Erythrocyte Na(+),K(+)-ATPase activity increased from 140+/-29 nmol of P(i).h(-1).mg(-1) in the basal state to 287+/-5 nmol of P(i). h(-1).mg(-1) during C-peptide infusion (P<0.01). There was a significant linear relationship between plasma C-peptide levels and erythrocyte Na(+),K(+)-ATPase activity during the C-peptide infusion (r=0.46, P<0.01). No significant changes in plasma cGMP levels or Na(+),K(+)-ATPase activity were observed during saline infusion. This study demonstrates an effect of human proinsulin C-peptide on microvascular function, which might be mediated by an increase in NO production and an activation of the erythrocyte Na(+),K(+)-ATPase. These mechanisms are compatible with the previous observed microvascular effects of C-peptide in patients with type I diabetes.


Subject(s)
C-Peptide/pharmacology , Diabetes Mellitus, Type 1/metabolism , Erythrocytes/drug effects , Nitric Oxide/metabolism , Sodium-Potassium-Exchanging ATPase/blood , Acetylcholine/pharmacology , Adult , Cross-Over Studies , Cyclic GMP/blood , Diabetes Mellitus, Type 1/physiopathology , Double-Blind Method , Erythrocytes/enzymology , Female , Hot Temperature , Humans , Laser-Doppler Flowmetry , Linear Models , Male , Microcirculation/drug effects , Microcirculation/physiopathology , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type III , Regional Blood Flow/drug effects , Statistics, Nonparametric
10.
Clin Sci (Lond) ; 94(3): 255-61, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9616259

ABSTRACT

1. Neurovascular inflammation is impaired in patients suffering from diabetic neuropathy. The aim of our study was to evaluate the distribution of nutritive and total skin blood flow in diabetic patients with and without neuropathy after neurovascular stimulation with acetylcholine. 2. Twenty patients with Type I diabetes, 10 with and 10 without neuropathy, and 10 age-matched non-diabetic control subjects, underwent microvascular investigations before and after neurovascular stimulation by intracutaneous application of acetylcholine. The capillary blood cell velocity in the nailfold of the hallux was measured by videophotometric capillaroscopy, and the total skin microcirculation in the same area by laser Doppler flowmetry. 3. The increase in total skin blood flow was significantly impaired in the group of neuropathic diabetic patients compared with the non-neuropathic diabetic patients (17.5 +/- 8.3 versus 51.0 +/- 16.2; P < 0.05) and the non-diabetic subjects (17.5 +/- 8.3 versus 67.8 +/- 19.7; P < 0.01). The increase in capillary blood flow was not significantly impaired in Type I diabetes patients with neuropathy. 4. The ratio between capillary blood flow and total skin perfusion decreased significantly in the control group (from 0.82 +/- 0.15 to 0.47 +/- 0.11; P < 0.05) and in the Type I diabetes patients without neuropathy (from 0.79 +/- 0.12 to 0.43 +/- 0.12; P < 0.05), whereas the decrease in the neuropathic group was statistically insignificant (from 1.05 +/- 0.19 to 0.72 +/- 0.16). 5. Diminished total skin perfusion in the foot after intracutaneous stimulation with acetylcholine in Type I diabetes patients is associated with diabetic neuropathy, indicating a disturbance in the neurovascular reflex arc. This impaired neurovascular response is caused by a diminished total and subpapillary blood flow and not by a diminished nutritive capillary flow. There is no evidence of a diminished nutritive capillary blood flow during neurogenic inflammation in Type I diabetes patients suffering from diabetic neuropathy.


Subject(s)
Diabetes Mellitus, Type 1/physiopathology , Diabetic Neuropathies/physiopathology , Skin/blood supply , Acetylcholine , Adult , Capillaries/physiopathology , Female , Hallux/blood supply , Humans , Laser-Doppler Flowmetry , Male , Microcirculation , Microscopy, Video
11.
J Clin Invest ; 101(10): 2036-41, 1998 May 15.
Article in English | MEDLINE | ID: mdl-9593759

ABSTRACT

19 insulin-dependent diabetes mellitus (IDDM) patients participated in a randomized double-blind crossover investigation to investigate the impact of human C-peptide on skin microvascular blood flow. The investigation was also carried out with 10 healthy volunteers. Blood pressure, heart rate, blood sugar, and C-peptide levels were monitored during a 60-min intravenous infusion period of C-peptide (8 pmol kg-1 min-1) or saline solution (154 mmol liter-1 NaCl), and 30 min after stopping the infusion. During the same time period, capillary blood cell velocity (CBV), laser Doppler flux (LDF), and skin temperature were assessed in the feet. In the verum arm, C-peptide levels increased after starting infusion to reach a maximum of 2.3+/-0.2 nmol liter-1 after 45 min, but remained below 0. 15 nmol liter-1 during the saline treatment. Baseline CBV was lower in diabetic patients compared with healthy subjects (147+/-3.6 vs. 162+/-4.2 micron s-1; P < 0.01). During C-peptide administration, CBV in IDDM patients increased progressively from 147+/-3.6 to 167+/-3.7 micron s-1; P < 0.001), whereas no significant change occurred during saline infusion or in healthy subjects. In contrast to the CBV measurements, the investigation of LDF, skin temperature, blood pressure, heart rate, or blood sugar did not demonstrate any significant change during the study. Replacement of human C-peptide in IDDM patients leads to a redistribution in skin microvascular blood flow levels comparable to levels in healthy subjects by increasing the nutritive CBV relative to subpapillary arteriovenous shunt flow.


Subject(s)
C-Peptide/pharmacology , Diabetes Mellitus, Type 1/physiopathology , Microcirculation/drug effects , Skin/blood supply , Adult , Blood Flow Velocity/drug effects , Blood Glucose/analysis , Blood Pressure/drug effects , C-Peptide/blood , Female , Foot/blood supply , Heart Rate/drug effects , Humans , Infusions, Intravenous , Insulin/blood , Male , Middle Aged , Regional Blood Flow/drug effects , Skin Temperature/drug effects
12.
Exp Clin Endocrinol Diabetes ; 106(6): 454-9, 1998.
Article in English | MEDLINE | ID: mdl-10079023

ABSTRACT

It is expected that microvascular blood flow might be affected by blood glucose, blood insulin and C-peptide levels. In our investigation skin microvascular blood flow (LDF) was measured using laser doppler fluxometry at skin temperatures of 37 degrees C and 44 degrees C during a 75 g oral glucose load (OGT) or water in ten healthy volunteers (6 male, 4 female, age: 28.1+/-4.0) who had fasted overnight. The transcutaneous oxygen tension (tcPO2) was measured using a transcutaneous oxygen electrode at a temperature of 44 degrees C. The microvascular response to acetylcholine was investigated before the start of the ingestion period and after 30 minutes. In addition, the capillary blood cell velocity (CBV) was measured using dynamic capillaroscopy. During OGT an increase in LDF could be observed at 37 degrees C (180%, p < 0.005) but only a slight increase was observed at 44 degrees C (86%, n.s.). The microvascular response to acetylcholine increased by 164% (p < 0.05) and the TcPO2 values increased by 30% (p < 0.01) during the OGT investigation. No significant changes in the microvascular measurements could be observed during the water experiment. No significant changes could be observed in the CBV measurements in any phase of the investigation. Plasma C-peptide and insulin levels exhibited an association with the LDF measurements at 37 degrees C (r = 0.22, p < 0.05; r = 0.30, p < 0.05; respectively), whereas blood sugar values showed an association with the TcPO2 measurements (r = 0.39, p < 0.01). After the ingestion of glucose a sophisticated modulation of microvascular blood flow was found in healthy volunteers. Further studies are necessary to investigate the role of a disturbed postprandial blood sugar control, insulin and C-peptide secretion in the development of microvascular dysfunction, especially in IDDM.


Subject(s)
Glucose/administration & dosage , Microcirculation , Skin/blood supply , Acetylcholine/pharmacology , Adult , Blood Flow Velocity , Blood Glucose/metabolism , C-Peptide/blood , Female , Humans , Insulin/blood , Laser-Doppler Flowmetry , Male , Microcirculation/drug effects , Oxygen/blood , Skin Temperature
SELECTION OF CITATIONS
SEARCH DETAIL
...